The most dramatically enriched oncogenic signatures in Siglec‐XII expressing cells include a set of genes altered in KRAS‐addicted cancers,39 and a set of TAZ‐associated genes found to be enriched in high‐grade tumors.40 The gene discussed is KRAS; the disease is cancer.